SANA Stock — Sana Biotechnology Inc.: Cash, EV, Pipeline

Share price

$3.10

Market cap

$928.0M

Cash

$160.5M

Enterprise value

$767.5M

Balance sheet

Cash	$160.5M
Debt	$0.0M
Net cash	$160.5M
Enterprise value	$767.5M
Basic shares	299.3M shares
Fully diluted shares	327.8M shares
Fully diluted market cap	$1,016.1M
Cash per share	$0.54

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading SANA daily closes…

Loading price history…

Pipeline assets

SC451

Preclinical · Active Modality: cell therapy (HIP-edited)

Indications

type 1 diabetes (Stage not disclosed)

Catalysts

— 2026

Status note HIP (hypoimmune) technology on a more scalable manufacturing platform; IND filing and Phase 1/2 trial expected as early as 2026. Prioritized program.

SG293

Stage not disclosed · Active Modality: in vivo CAR T (fusogen platform)

Target CD20

Indications

B cell malignancies (incl. non-Hodgkin lymphoma) (Stage not disclosed)
B cell mediated autoimmune diseases (Stage not disclosed)

Catalysts

— 2026

Status note In vivo CAR T candidate using the fusogen platform for cell-specific in vivo delivery. Surrogate preclinical data (CD20 CAR targeting NHP B cells without lymphodepletion) presented at ASGCT May 2026. Prioritized program.

SG227

Stage not disclosed · Active Modality: in vivo CAR T (fusogen platform)

Indications

multiple myeloma (Stage not disclosed)

Status note In vivo CAR T candidate for the treatment of multiple myeloma. Stage not stated in excerpts.

SC291

Phase 1 · Terminated Modality: allogeneic CAR T

Target CD19

Indications

B-cell mediated autoimmune diseases (Phase 1)

Status note Development suspended and enrollment halted in the Phase 1 GLEAM trial (announced Nov 2025) to prioritize SC451 and SG293.

SC262

Phase 1 · Terminated Modality: allogeneic CAR T

Indications

oncology (Phase 1)

Status note Development suspended and enrollment halted in the Phase 1 VIVID trial (announced Nov 2025) to prioritize SC451 and SG293.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT03047369	Not disclosed	Recruiting	Collaborator	Children's Hospital of Philadelphia	BIIB, LLY, MRK, SNY, TAK	Leukodystrophy; White Matter Disease; Leukoencephalopathies	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Children's Hospital of Philadelphia on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	310,483	no change	0.01%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

SANA — Sana Biotechnology Inc.

Balance sheet

Price history

Pipeline assets

Active clinical trials

Institutional holders